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India stands at a critical junction of HIV pandemic. Controlling spread of HIV is 
critical.  Ignoring this will lead millions of Indians in grip of this pandemic.  Ever since 
HIV/AIDS was acknowledged as a problem, the strategies to address the issue have 
focused on prevention, treatment and research.  This paper discusses the treatment 
aspect.  With currently available antiretroviral agents, eradication of HIV infection is 
not likely.  The aim of treatment is thus to prolong and improve the quality of life by 
maintaining maximal suppression of virus replication for as long as possible.  Brazil has 
shown how to implement antiretroviral therapy programme.  India has embarked 
upon an ambitious programme to introduce antiretroviral therapy in six high 
prevalent states and the national capital.  The paper discusses the technical, 









Treating HIV/AIDS patients in India with  
antiretroviral therapy: a management challenge 
1.  Introduction 
The Government of India on November 30, 2003 announced a plan to place 100,000 
AIDS cases in India on structured anti-retroviral therapy by the end of 2005 and 15 to 
20 per cent additional AIDS cases each year, thereafter, for a period of five years.  The 
first quarter of the free AIDS-drugs initiatives was started from April 2004.  The supply 
of antiretroviral drugs to support the first quarter of this initiative is sourced through 
the World Health Organisation (WHO) procurement mechanism, and is expected that 
from the subsequent period, government will enter into a pact for delivery of the 
medicines with the pharmaceutical companies.  Initially the programme will be 
restricted to six high prevalent states of India with a funding commitment of Rs. 2 
billion ($44 million) for the infrastructure needed to implement this programme.  Of 
this amount, Rs. 1.13 billion ($25 million) is meant for medicines and Rs. 0.87 billion 
($19 million) for providing infrastructure to screen people for HIV/AIDS infection 
(NACO 2003).  National AIDS Control Organisation (NACO), the nodal agency for 
implementing HIV/AIDS prevention and control programme in India has drafted 
“Programme Implementation Guidelines for a phased scale up of access to 
Antiretroviral Therapy” which deals with detail plan of implementation of 
antiretroviral drugs to people living with HIV/AIDS.  
We observe a degree of ambiguity in the Programme Guideline towards the 
introduction of antiretroviral therapy as a part of community based or clinic based 
programme in India.  We feel there is considerable management challenge in 
implementing the proposed programme guidelines.  We have made an attempt to 
present in this paper an analysis of management challenge in implementation of the 
programme and literature scan on some of the key aspect of introducing antiretroviral 
therapy in India.  We build up our study in the light of three major challenges in  
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implementation of the programme: technical challenge, financial challenge and 
management challenge.  In doing so, we attempt to address the existing infrastructure 
of Indian HIV control programme, implication of work flow, management structure 
and experience of Brazil in implementing antiretroviral therapy as a part of national 
public health programme.  In conclusion we attempt to build up a discussion in the 
light of the above issues and challenges.   
2.  Technical issues on initiating antiretroviral therapy 
In this section, we discuss issues regarding when to start antiretroviral therapy in HIV 
positive patients, impact of such therapy on mortality and incidence of opportunistic 
infections (OI).  We build up this section based on various published studies and 
guidelines available through literature scan.  The vital issues we attempt to address here 
are the period between HIV infections to development of full blown AIDS, the risk of 
opportunistic infections and time to initiate antiretroviral therapy.  
Natural history of the disease   
Up to three months of HIV infection, there is often an asymptomatic viraemia (spread 
of virus in blood stream), during which period although patients are infective, ELISA 
test for HIV antibodies are negative.  Progression to symptomatic disease i.e., the 
amount of time it takes from HIV infection to become full blown AIDS depends on the 
general health and nutritional status before and during the time of HIV infection.  
According to WHO, the average time for an adult is approximately ten years.  The 
median survival for a person with full-blown AIDS and without antiretroviral therapy 
is 2 years (WHO 2002).   
Most of the information regarding natural history of HIV infection is available for 
developed countries only.  Sometimes using these indicators can be problematic in case 
of developing countries where the local condition and nutrition diet status are likely to 
be different. Epidemiologists and health planners use the cumulative number of AIDS  
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cases as the reference point.  The criterion used in defining the HIV/AIDS case has 
implications for who should be included and has need for antiretroviral therapy.  
There is, however, some agreement on that the criterion based on CD4 cell count may 
be an effective way to identify the cases that need ARV treatment and should be 
covered.   Figure 1 present graphically the natural history of disease progression 
corresponding to the number of T-helper lymphocytes per cubic millimeter of blood, 
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Initiating antiretroviral therapy   
The Department of Health and Human Services (DHHS), United States, recommends 
offering treatment to asymptomatic patients with CD4 cell counts of fewer than 200 
cells/µL (DHHS 2004).  WHO has devised a clinical staging system for HIV infection and 
disease in adults and adolescents.  Details of the WHO clinical staging of HIV/AIDS is 
given in Appendix 3.  WHO recommends that in resource-limited settings persons with 
symptomatic disease (AIDS, WHO adult stage IV and advanced stage III disease) should 
receive ARV treatment irrespective of the CD4 cell or total lymphocyte count (WHO  
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2002).  Therapy is also recommended for people with earlier symptomatic (WHO adult 
stages II and III) and asymptomatic (WHO adult stage I) disease when the CD4 cell 
count nears or falls below 200 cells/µL or when the CD4 percentage is below 15 per 
cent.  When CD4 cell monitoring is unavailable, treatment is recommended for 
symptomatic persons (WHO adult stages II and III) with total lymphocyte count (TLC) 
below 1200/mm
3.  Based on the recommendations of panel on clinical practices for 
treatment of HIV infection convened by the Department of Health and Human 
Services, an algorithm of the treatment recommendation for HIV patients is presented 
in Appendix 2 (DHHS 2004). 
Positive externalities of antiretroviral therapy  
The introduction and widespread use of highly active antiretroviral therapy (HAART) 
for HIV-infected persons in San Francisco in the late 1990s reduced their risks of 
infecting partners by 60 percent (Corinna 2003).  According to a review of the 
immunological data (Guislaine, Taisheng and Brigitte 1999), combined drug regimens 
induce a major and durable viral load reduction and bring about a stable CD4 count 
increase in infected person.  The authors concluded that HAART, at whatever the 
stage of the disease it is initiated, allows immune restoration and protection against 
opportunistic pathogens.    
Monitoring of patients on antiretroviral therapy  
WHO has recommended minimum laboratory tests for monitoring of patients on 
antiretroviral therapy.  This includes HIV antibody test, and hemoglobin or hematocrit 
level.  Highly desirable tests are white blood cell count and differential, CD4 count, 
serum alanine, aspartate aminotransferase level, serum creatinine, blood urea nitrogen, 
serum glucose, bilirubin, amylase and serum lipids, and pregnancy tests for women.  
Ideally CD4 cell count for a patient on HAART should be monitored quarterly.  
Toxicity should be monitored clinically based on patient reports and physical 
examination, supplemented by a limited number of laboratory tests depending on the 
symptoms that arise and the specific combination regimen that is used.  According to a  
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study by YRG care, Chennai, India, total lymphocyte count, hemoglobin (Hg), and 
weight changes may be able to predict CD4 count change in patients on HAART.  The 
cost of a single CD4 count in resource limited setting in India is approximately $28 and 
the same for total lymphocyte count is $2.40 per test (Kumarasamy, et.al. 2004).  
3.  Experience of Brazil in implementing antiretroviral therapy  
Brazil is the first developing country to have implemented a large-scale universal 
antiretroviral distribution programme.  There is huge potential for countries like India 
to learn from the success and challenges of the Brazilian programme in providing free 
antiretroviral therapy as a part of public health programme.  We present a brief 
literature scan of the financial and logistic management of the Brazilian programme in 
this section.  
The Brazilian response is made possible through a concerted government response and 
a strong social and political commitment towards the problem.  The programme of 
introducing antiretroviral treatment therapy was adequately supplemented by 
prevention efforts to control spread of new infections.  In 1988, the Brazilian public-
health system began to distribute drugs to treat opportunistic infections, and in 1991, 
began to offer Zidovudine (brand name of AZT, the first antiviral treatment to be 
approved for use against HIV).  In 1996, the government of Brazil initiated a 
programme of free distribution of drugs to people living with HIV/AIDS.  Brazilian 
government produced domestic generic drugs to contain the drug cost. 
Management structure and logistic systems   
The programme created a network of more than 1,000 public alternative care and HIV 
testing services to provide the necessary infrastructure to support this policy.  Four 
hundred twenty four sites, known as AIDS Drugs Dispensing Units (ADDU) were 
created around Brazil to function as the treatment centres (Jane 2002).  The 
programme implemented a computerised system for control of drug logistics system 
known as the Sistema de Controle Logístico de Medicamentos (SICLOM), which  
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registers distribution of antiretroviral, helping to maintain needed stocks of drugs at 
ADDUs and to track prescriptions.  A network of 138 public laboratories was 
established to test CD4 cell count and viral load of patients.  In the year 2001, 138 such 
laboratories conducted 400,000 tests at a total cost of around US$ 18 million.  Another 
computer system - Sistema de Controle de Exames Laboratoriais (SISCEL) tracks test 
results and changes of CD4 and viral load for use by clinicians.  
Financial implications of the programme   
Government’s spending on antiretrovirals was: US$ 34 million in 1996; $224 million in 
1997; $305 million in 1998; $336 million in 1999; $303 million in 2000; and $ 235 
million by 2001.  On an average Brazil spend 2 per cent of total health budget on 













Avg. # of 
patients 
% of health 
dept budget 
1996  $ 3,810  1997  224  35,900  1.2 
1997  $ 4,860  1998  305  55,600  1.8 
1998  $ 4,540  1999  336  73,000  3.2 
1999  $ 4,240  2000  303  87,500  2.9 
2000  $ 3,320  2001  235  105,150  1.6 
2001  $ 2,530 
 
2002 167  125,000  1.8 
Source: Brazilian Ministry of Health 
Scale and scope of the programme  
The $300 million annual expenditure on antiretroviral therapy in Brazil has proved to 
be cost effective, because it outweighs what would otherwise have to be spent on 
hospitalisation, on drugs for opportunistic infections, and on coping with large 
numbers of people unable to work.  An evaluation of the results of the Brazilian AIDS 
policy shows a striking reduction in mortality (40-70 per cent), morbidity (60-80 per 
cent) and hospitalisation rates of HIV+ patients, with more than 90,000 avoided deaths 
and 60,000 AIDS cases prevented.  During the period more than 358,000 AIDS-related 
hospital admissions were avoided.  This resulted in savings to the Government of more 
than US$1.1 billion from 1997 to 2001.  However, when an additional US$1.2 billion 
saved on ambulatory care, including drugs for opportunistic infections, were taken 
into consideration, the total amount rises to approximately US$2 billion (Chequer, 
Hearst and Hudes 1992; Marins 2002). 
Achievement of the programme   
Initiated in the early 1990s with the distribution of AZT, Brazil now provides free 
antiretroviral medication to about 125,000 patients, which reflects coverage of virtually 
all people living with HIV/AIDS.  By March 2002, close to 240,000 AIDS cases (Table 1) 
reported to the Ministry of Health (MOH) and an estimated 35,900 individuals received 
these drugs in 1997; 55,600 in 1998; 73,000 in 1999; 87,500 in 2000; and 105,000 in 2001 
(Jane 2002).  During 2002, about 125,000 patients received ARV freely in Brazil which  
 
10
means more than a third of the estimated total number of ARV treated patients in the 
entire developing world at the end of 2002 live in Brazil (Teixeria, Vitoria and 
Barcarolo 2003).  In the mid-nineties, the World Bank estimated 1.2 million Brazilians 
would be infected with HIV by the year 2000.  Today, the number of those estimated 
to be infected with the virus is half that amount.  
4.  Management issues in initiating antiretroviral therapy 
The Brazilian experience shows that the delivery of antiretroviral drugs to large 
number of persons living with HIV/AIDS (PLWHAS) is a challenging task owing to 
physical infrastructure requirements and coordination among care providers at 
different levels.  Managers of the programme have to successfully overcome challenges 
in service delivery and challenges related to roles and responsibility of people in the 
health sector.  Managers have to worry about organisational behaviour of healthcare 
professional and its related structural rigidities owing to high people interface in health 
service sector.  To examine the roles and responsibility and other organisational issues, 
we present a brief review of the NACO programme guidelines, organisation of 
healthcare system in India and organisation of HIV/AIDS programme.  
NACO Programme Guidelines 
HIV/AIDS prevention, care and treatment programme is implemented in India through 
National AIDS Control Organisation (NACO) as the nodal organisation.  It is estimated 
that about 4.2 million people live with HIV infection in India and 600,000 cases 
urgently need treatment (WHO 2004).  According to the draft policy document for 
scaling up of antiretroviral therapy in India, the first phase of the NACO programme 
will be focussed on antiretroviral drug distribution among HIV-positive mothers who 
have participated in the national prevention of parent-to-child transmission 
programme (PPTCT), HIV-positive children, and people with AIDS who seek treatment 
in government hospitals (NACO 2003).  Costing an estimated US$100 million a year, 
the programme will initially cover 15 centres in six states where HIV prevalence  
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exceeds 1 per cent of women attending antenatal clinics.  The second phase of the 
programme will extend the antiretroviral drug distribution to government hospitals 
with medical colleges, and the third phase will include all district hospitals in these 
states. NACO programme also plans to strengthen 540 Voluntary Counselling and 
Testing Centres (VCTC) existing in the country.  The programme envisages 
community involvement for tracking of people living with HIV/AIDS with the help of 
trained paramedical personnel, community workers and people living with HIV/AIDS.  
The programme will be implemented within the existing structure of healthcare sector 
in India. 
Healthcare structure in India 
Health is State subject and therefore States are primarily responsible for the healthcare 
system.  The Ministry of Health and Family Welfare at the centre is responsible for 
planning and coordination of national health programmes implemented through State 
level infrastructure.  
The departments of health in the States are implementing agencies of national health 
programmes and central sponsored programmes.  The state level agencies are also 
responsible for providing inputs in formulating the key polices to strengthen the 
national health programmes.  These departments are mostly headed by an officer of 
the rank of Principal Secretary (PS).  The PS is subordinated by a Secretary (Family 
Welfare) and a Commissioner/Director (Health).  The Commissonerate or Directorate 
are the technical wings of the health and family welfare department.  At the 
operational level, the Directorate of Medical, Public Health and Family Welfare 
Services is responsible for program planning, implementation and monitoring.  The 
directorate works under the supervision and guidance of the respective Secretaries. 
Additional Directors, Joint Directors and Deputy Directors assist the Directors in 
various programmes and activities.   
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Two officers, i.e., the Civil Surgeon-cum-Hospital Superintendent and the Chief 
Medical & Health Officer (CMHO) mainly look after the district level health 
administration.  The Civil Surgeon-cum-Hospital Superintendent is mainly responsible 
for management of district hospital (DH).  The CMHO is mainly responsible for 
management of health care set up in rural areas of the district, which includes 
Community Health Centres (CHCs), Primary Health Centres (PHCs), and Sub-centres 
(SCs), and also the Civil Hospitals (CHs).  The CMHO heads the district management 
team and supported by officers for various programmes.   
Along with the above Public Health System, there exists a complex array of medical 
systems consisting of several traditional text-based medical systems, modem allopathic 
medicine, Ayurveda, Unani, Homeopathy, Naturopathy, Traditional Faith Healers 
and large number of Private Providers both qualified and non qualified in India.  In 
India the private sector provides eighty percent of healthcare through not-for-profit, 
organised, and informal sectors.  While the not-for-profit and organised health sectors 
are largely concentrated in urban areas, rural areas support a wide range of private 
health care providers, from allopathic and traditional medical practitioners to faith 
healers. 
HIV/AIDS programme structure and its linkage with healthcare structure 
At the central level, National AIDS Control Organisation (NACO) is responsible for 
planning and implementation of HIV/AIDS control programme in India. NACO is 
created as a semi-autonomous body within the Ministry of Health and Family Welfare.  
In order to strengthen programme management at the state level, State AIDS Control 
Societies (SACS) were organised in every state of India.  SACS is responsible for the 
programme implementation and coordination of AIDS control activities and fund 
disbursement among NGO partners. SACS are headed by Programme Directors.  
Besides, several states also have set up a Project Support Units (PSU), which are 
responsible for project implementation in the state in coordination with NGOs.   
 
13
The broad responsibilities of SACS are 
⋅  Budget allocation and fund release for different HIV/AIDS interventions 
⋅  Management of programme on HIV intervention 
⋅  Carrying out sentinel and ANC clinic surveillance and report estimated HIV 
cases in the state 
⋅  Carrying out HIV prevention activities 
 
The broad responsibilities of PSU are 
⋅  Implementing HIV/AIDS project for SACS  
⋅  Implementing Targeted intervention through NGOs 
⋅  Carrying out Need Assessment Survey 
 
The HIV/AIDS control programme in India is implemented through the government 
health infrastructure and public-private partnerships.  Treatment and curative centres 
at the district level are part of the district hospital and tertiary hospitals structure in 
states.  The preventive and promotive programmes are implemented through Chief 
Medical & Health Officers (CMHO) of every district.  Besides this the Project Support 
Unit is responsible for implementing the projects through NGOs working at the 
community level.  
Service delivery model for the antiretroviral therapy programme 
The model for delivery of antiretroviral therapy adopted by NACO is a centralised 
institutional model supported by NGOs and CBOs.  However, the widespread 
utilisation of traditional practitioners in the country suggests that they are  trusted, 
accessible, and affordable practitioners among a section of population.  Moreover, for a 
problem like STD, HIV/AIDS, lot of taboo/stigma is attached if a person approaches an 
institution, specially set up for this purpose.  People carry negative perception of 
government healthcare centres for reasons such as improper behaviour of health staff, 
staff shortages, a lack of supplies and drugs, and long waiting times to see a doctor 
(Bhat and Maheshwari, 2004).  The availability of female doctors, nurses, and midwives  
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affects choice of health services.  This coupled with lack of transport facilities resulted 
in most of the deliveries in India, non-institutional.  According to NFHS 2 survey over 
eighty percent of deliveries occur at home in rural areas.  Traditional Birth Attendants 
(TBA), popularly known as dais in the community attends 48 percent of the deliveries, 
another 40 per cent are attended by relatives or others and only 11 percent are 
attended by a doctor or nurse-midwife at home.  This poor rate of institutional 
delivery raises serious doubt about control and treatment of AIDS among sero-positive 
mothers and children below the age of 15 years as envisaged in the programme 
documents.  
Given that about 57 per cent of hospitals and 32 per cent of hospital beds are in the 
private sector (Bhat 1999) and 80 per cent of 390,000 qualified allopathic doctors 
registered with medical councils of India are working in the private sector (Jesani 1989; 
Bhat 1996), antiretroviral drug distribution among HIV-positive mothers who have 
participated in the national prevention of parent-to-child transmission programme 
(PPTCT) will account for a small fraction of the problem. 
The NACO programme document envisages bringing to centre-stage the HIV-TB co-
infection through linkages with the TB control programme for free treatment of TB 
among people living with HIV/AIDS.  According to a report 50 per cent of the 
tuberculosis patients approach private providers first for relief (Narayanan, Santha and 
Paul 2003).  Their relative advantages include easy access, convenient timings, better 
communication, greater confidentiality and perception of better quality of care.  Study 
on government service delivery mechanism shows that often doctors are available at 
the health facility only for 3-4 hours on a working day.  Employees at health centres 
are not available on holidays and vacations, which are nearly 40 per cent of days in a 
year in India in government services (Mavalankar 1999b).  Hence, to build up an 
effective service delivery model for antiretroviral therapy drug distribution through 
government facilities would be grossly inadequate.  There is a need for an effective mix 
of public private partnership and greater involvement of private providers in the  
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system.  Rather than a centralised institutional model, a community-based model 
would be more appropriate for drug administration and follow up of PLWHAS.  The 
community based model would essentially require re-examination of roles and 
responsibilities at different levels.  
Programme on making antiretroviral drugs available to the needy people involve the 
following process: (a) case identification, (b) treatment and drug distribution, (c) 
monitoring the progress, and (d) managing opportunistic infections and side effects due 
to the drugs.  We attempt to describe the process involved in each of the issues along 
with the probable providers for the services. 
Case identification: It is the first step for drug therapy of PLWHAS. WHO recommends 
initiating antiretroviral therapy for persons with symptomatic disease irrespective of 
the CD4 cell count and for persons with asymptomatic stage antiretroviral therapy 
should be initiated when CD4 cell count nears or falls below 200 cells/µL (WHO 2002).  
Implementation of this recommendation essentially leads to two challenges.  The soft 
challenge is regarding the availability and behaviour of service providers and the hard 
challenge relates to the physical infrastructure. 
Given, the difficult reach to the healthcare centres in many areas, lack of transport 
facilities and inadequate service providers, private providers, NGOs, CBOs, PLWHAs and 
health workers - ANMs and MPWs have a greater role in primary screening of patient 
through motivating patients to undertake testing for CD4 cell count and thereby enrol 
for treatment of antiretroviral drugs therapy.  A proper symptom checklist and 
training of the health workers and private providers may suffice the need.  However, 
this should be supplemented by adequate infrastructure for service delivery and 




Treatment and drug distribution: Antiretroviral therapy regimens available in the 
market involve a cocktail of three drugs to be taken twice daily.  Hence, the primary 
point of concern for building up a successful response with antiretroviral therapy is 
timely supply of drugs to the patients on treatment.  It has been one of the key reasons 
for success of Revised National Tuberculosis Control Programme (Narayanan, Santha 
and Paul 2003). Although treatment initiation and supervision is to be done at the 
secondary health facilities for example district hospitals and above; primary health 
centres, ANMs, MPWs, NGOs, CBOs can be empowered for drug delivery and monitoring 
of the patient progress.  Private providers can play a key role with proper monitoring 
at the local level. 
Monitoring the progress:  Proper monitoring of patients on treatment is a vital 
element for treatment adherence and performance of the drugs.  Patient has to be 
monitored for their viral load count in the blood.  The YRG Care study shows that 
total lymphocyte count, haemoglobin (Hg), and weight changes are cost effective and 
able predictors of CD4 count changes in patients.  The facility for total lymphocyte 
(type of white blood cell involved in human body immune system) counts is available 
in majority of the primary health centres in India.  The toxicity of drugs could be 
monitored clinically based on patient reports and physical examination, supplemented 
by a limited number of laboratory tests depending on the symptoms that arise and the 
specific combination regimen that is used.  This becomes important as drug toxicity is 
often identified as symptoms of AIDS leading to treatment failure among the patients.  
Hence the patient, family/community members need to be properly sensitised about 
the different aspects of treatment adherence. Moreover efforts to de-stigmatise the 
community about the disease will help in a long way to deal with the problem.  
Primary healthcare system, private providers and NGOs can play a vital role in the 
monitoring process.  With proper facilitation and supervision from the healthcare 
system, an effective monitoring system can be developed.  
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Managing opportunistic infections (OIs) and side-effects due to the drugs:  HIV 
infected patients die due to the opportunistic infections owing to reduced immune 
system of the body.  Simultaneously the antiretroviral drugs, as mentioned above, 
often cause high toxicity leading to treatment failure.  Hence, the management risk of 
opportunistic infections and drug side effects is crucial for this sector.  These twin 
issues have to be effectively dealt with on two fronts – treatment and sensitisation.  
Until patients are well sensitised about the issues, proper treatment adherence is 
difficult to achieve.  The sensitisation of the patient and community members could be 
done at the community level with the involvement of ANMs, MPWs, NGOs, CBOs, and 
private providers.  The sensitisation has to be on a wide range of issues, like preventive 
aspects, risk of transmission during the treatment period etc.  
Based on the data and information available, we attempt to map the different HIV/AIDS 
services into different service delivery settings.  Table 1 proposes an optimal level of 
service delivery in terms of provision of services in various settings.  As emphasised in 
the above table, it is expected that grass root bodies like government sub-centres, 
primary health centres and different community based organisations and private clinics 
will play a wider role in the area of promotional activities, preliminary screening of 
patients requiring antiretroviral therapy, counselling and care of patients, case 
identification and monitoring the progress of patients at community level.  However, 
there are several challenges in expecting the services of grass root public delivery 
organisations and involving private providers in implementation of antiretroviral 
therapy.  Some of the challenges are mentioned below: 
Non availability of staff:  Employees at health centres are not available on holidays 
and vacations, which are nearly 40 per cent of days in a year in India in government 
services (Mavalankar, 1999a).  In the absence staff, there is none at primary health 
centres and Community health centres to provide care.  It is estimated that only 52 
percent of staff of PHCs, located in villages, stay at the place of their postings 
(Mavalankar, 1999a).  Rest of them prefer to stay in nearby towns from where they  
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commute daily.  There are evidences to show that staff members are irregular to health 
facilities on working days.  The doctors and staff are found reluctant to work in rural 
areas owing to not only physical hardships but also owing to lack of professional 
growth opportunities.  Further, often doctors are available at the health facility only 
for 3-4 hours on a working day (Mavalankar, 1999a). Table 1: Mapping  of service provision 
Government Private  Service Provider 
Intervention  SC PHC  CHC  DH/VCTC  TH/VCTC  BB Clinic  PH  NGOs 
Prevention 
    **  ****  **** ****  ****  
   *** ****  ****     ***  




Targeted Intervention  ***           **  ****  **** 
Promotion 
****  **** **  **  *  *** ***  ****  **** 
****  **** **  **  *  *** ***  ****  **** 
Condom Promotion 
IEC 
Family Health Awareness 
Campaign 
****  **** **  **  *  *** ***  ****  **** 
Screening of patients  
****  ***         ****  ****  Preliminary Screening 
Clinical Screening   **  ** ****  ****      ***   
Counselling and Care  * **  **  ****  **** ***  **  ****  **** 
Treatment for OIs 
 *  ***  **** ****  *  ***   
  ** **  ***  ***    **  ****  
High Complexity 
Medium Complexity 
Lower Complexity   ***  ****  **  **   ***  ***  
Treatment with ARV  * **  *** ****  ****    **  ****  ** 
This table uses asterisks to indicate desirability of services in various settings. Four asterisks to no asterisk indicate: high presence, medium presence, 
moderate presence, low presence and no presence. The definition of other terms used in the table is as follows: SC: sub-centre, PHC: primary health 
centre, CHC: community health centre, DH: district hospital, TH: teaching hospital, VCTC: voluntary counselling and testing centre, BB: blood bank, 
Clinic: private clinic, PH: private hospital, NGO: non-government organisation, PPTCT: prevention of parent to child transmission, STI: sexually 
transmitted infection, IEC: information, education and communication, OI: opportunistic infection, ARV: antiretroviral therapy  
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Competency of physicians: The supply of trained and competent physicians who can 
prescribe ARV is a major concern for success of the programme.  With a greater 
number of doctors willing and able to treat HIV positive patients as per recommended 
guidelines, there will be greater willingness on the part of individuals to access such 
treatment.  According to a research study (Gupta and Sankar 2003), unless the doctors 
seeing the patients explain or mention about ARV, there is no easy way for patients to 
even consider antiretroviral therapy. 
Capacity issues and regulatory concerns:  An estimated one million illegal 
practitioners are said to be managing 50-70 per cent of primary consultations, mostly 
for minor illnesses and form the de facto primary curative healthcare system of rural 
India.  According to a rough estimate, the number of voluntary organisations working 
in healthcare areas in India is more than 7000 (Mishra 2000).  These NGOs have the 
potential to improve access, quality and equity of services, either through direct 
provision or through advocacy and other action.  The challenge is to devise innovative 
mechanisms that address distortions and malpractices, yet do not stifle private 
initiatives particularly in backward states and remote areas, and to ensure systems that 
will keep such participation accountable and transparent. The specific areas identified 
in which private practitioners and NGOs could make a significant contribution in 
treatment with antiretroviral therapy programme are: advocacy; case management; 
counselling and health education; improving case notifications, and liaising with other 
stakeholders such as business and industry for increased commitment to national 
control efforts and resource mobilisation. 
Solution to these challenges requires interventions in the structure and policies of the 
health sector, HR policies and practices and monitoring mechanisms.  Treating a 
patient requires different tasks to be carried out by variety of experts who possess 
different skills and who need to cooperate with each other (Lee 2001).  Effectiveness of 
health system is dependent upon availability of adequately skilled personnel who  
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Challenge in roles and responsibility in health sector:  In order to address the 
challenge in service delivery model and greater involvement of community in the 
delivery of antiretroviral drugs, the roles and responsibilities of health professionals 
needs to be redefined.  This requires addressing the issues of roles, responsibilities and 
structural rigidities.  Currently health professionals at district level perform three 
distinct activities.  These are regulating and monitoring, provision of health care 
services and facilitating and coordinating the provision of services.  These are 
summarised in the following table adopted from Bhat and Maheshwari (2004)  
Table 2:  Roles and responsibilities in health sector 




Implementing the laws 
and standards to protect 
the health of people like 
laws related to 
adulteration of food 
articles. 
Caring the patient 
 
Coordinating between 
personnel responsible for 





















High power distance 
between different levels 
Long hierarchy 
 
Empowerment at lower 
levels 
Low power distance 












Do not trust people 
unless proved worthy of 
that 
Do not leave things to 
chance 
Trust people unless 
proved unworthy of that 
 
Neither trust them not 
mistrust them, be open to 





The three different roles of district health officials require three different patterns of 
behaviour. In order to perform these roles effectively, the health systems lack enabling 
structures and communication process.  The existing structure, with serious inherent 
rigidities is inadequate to manage these roles effectively.  The structural rigidities of 
health system are explained by Bhat and Maheshwari (2004) as: 
·  Operating islands characterised by very little coordination and communication 
between centre, state, district, sub-division, blocks, sectors and villages with highly 
unpredictable resource flows, high variability in performance and inconsistent 
practices. 
·  Fragmented sector characterised by very little coordination across Health, 
Family Welfare and Indian System of Medicine (ISM) and  
·  Broken hierarchy characterised by little influence to steer the programme and 
lack of clarity on linkages and resource flows, inadequate role in strategic planning 
and policy and considerable gaps in capacities.   
The structural rigidities and discontinuities have instigated mechanistic system of 
decision-making in the health sector.  Over the years many of these rigidities have 
been reinforced and have to a large extent been institutionalised by centralising 
decision-making powers at the state and central level.  This centralised decision-making 
over a period of time has seriously affected the creativity and commitment among the 
healthcare providers in the system. 
Further, the HR systems are not performance-driven.  They are seniority driven, 
instead. Consequently the performance focus in the state is found to be low.  The 
healthcare personnel primarily concentrate on meeting the documented targets relating 
to different national programmes than to quality of care to patients visiting the health 
facilities.  Without addressing this issue, it will be difficult to implement a  
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decentralised HIV/AIDS programme.  The treatment process as envisaged for effective 
implementation of HIV/AIDS programme would essentially require a network of 
sustained relationships between care providers at different levels. It may essentially 
happen through informal channels of communication and networking. 
HIV/AIDS sector requires extremely high sensitivity of the care providers owing to 
associated stigma issues.  This sensitivity could be ensured through pro-social behavior 
(Table 2).  This behaviour essentially requires high organisational and occupational 
commitment of health professionals and professional competency development of 
healthcare providers.  The current structures, processes and systems that prevail in 
most of the state do not instill confidence that such behaviour could be achieved in 
near future.  NACO would be able to implement the programme better by enhancing 
the professional commitment of healthcare providers.  The professional commitment 
could be enhanced by investment in professional competencies of doctors and other 
technical staff and intense socialisation on technical issues through conferences, debates 
and discussions.  The application of technology could be effectively utilised for 
technical discussions.  
5.  Financial challenge for initiating and up scaling antiretroviral therapy  
The task of providing antiretroviral therapy to HIV infected people requires substantial 
financial commitment.  The tenth five-year plan of India 2002-2007 provides an outlay 
to the tune of 14 per cent of total central health budget for implementation of 
HIV/AIDS control programme (Rs. 1270 crores for implementation of the HIV/AIDS 
Control Programme as against a total budgetary outlay of Rs. 9253 cores for the 
Ministry of Health & Family Welfare).  But the entire amount is primarily meant for 
prevention and promotion approach.  The details of allocation and expenditure for the 
Indian National AIDS Control Organisation are discussed in detail in Bhat and Saha 
(2004).  Recently, India and the Global Fund to Fight AIDS, Tuberculosis and Malaria 
signed two grant agreements that will allow the disbursement of $33 million over the  
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next two years and a total of $129 million over five years (Times of India).  The grants, 
which were approved on 30
th January 2003, during the Global Fund's second round of 
grant proposals, will be used to expand the country's national HIV/AIDS and TB 
prevention and control programme.  In its third round of grants, the fund approved 
another $15 million for Indian HIV/AIDS and TB prevention and treatment 
programmes.  Overall, the Global Fund has committed to India $153 million over five 
years (Times of India). Most of the money from the Global Fund will go toward the 
provision and administration of antiretroviral drugs to HIV-positive people (Global 
Fund 2004).   Responding to the problem effectively, however, requires significant 
financial commitment.  The success story of Thailand is probably of greatest relevance 
to India. According to reports, Thailand spends roughly 55 cents per person on 
prevention and treatment, Uganda $ 1.85, but India only about 17 cents.  In 2000 (the 
latest year for which comparative figures exist), India spend only $17 per person on 
health, of which four-fifths was in the private sector; indeed, on one measure 
government health spending was only $4 per person.  India is one of only eight 
countries whose public-health budget is less than 1 per cent of GDP.   
The cheapest triple combination antiretroviral therapy available as of now is of the 
Indian pharmaceutical companies agreeing with Clinton Foundation at prices close to 
Rs. 17 per day per patient ($140 or about Rs. 6,078 for a year).  The Clinton 
Foundation has secured a deal with five manufacturers of CD4 and viral load tests, the 
cost of a CD4 cell count will fall from $11 - $12 to between $3 - $5, with no up front 
payment for machines.  Under the agreement, the cost of a viral load test is 
confidential, but is thought to have been reduced to around $20 a test.  The machines 
for carrying out the tests will be maintained and serviced by the manufacturers, and 
they will also provide training in how to carry out the tests.  (Wall Street Journal 14
th 
January 2004). 
The Government of India has estimated that the total fund required for placing 
100,000 patients on antiretroviral therapy by 2005 will be Rs. 2 billion ($44 million).   
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However, the programme documents are silent on quantifying the system up-
gradation required to meet the challenge of providing and monitoring antiretroviral 
therapy to the patients.  For calculating the cost of the programme, we need to 
understand the natural history of the disease progression, life time risk of patient to 
contract the disease, incidence of Opportunistic Infections relative to CD4 cell count in 
the patient and survival analysis thereof.  According to a study (Bhat and Saha 2004) 
under conservative estimate, the annual combined cost of screening, cost of anti-
retroviral therapy and monitoring the progress of patients in India, the annual cost of 
the programme will be Rs. 1.87 billion ($427 per patient) under the presumption of 
CD4 cell count test at Rs. 1200 per test and Rs. 0.92 billion ($210 per patient) under the 
presumption that CD4 cell count test will be available at Rs. 243 per test.  The study 
presumed that 400000 HIV infected case would be placed under screening and 100000 
cases will be placed under structure antiretroviral therapy annually.  However, the 
study does not include cost of additional infrastructure needed to upscale the 
programme and costs related to human resource mobilisation.  Quantification, 
procurement, and supply chain management of HIV test kits and other commodities 
are a major challenge as well for the programme managers.  The summarised study 
result is given in Table 3. 
Table 3: Per annum cost (in millions of rupees) of treating 100,000 population
 
Scenario 1  Scenario 2    




Screening of 400,000 
high-risk cases 
Market Price of CD4 cell 
count (Rs. 1200 per  test) 
7141 10081  1879 
Clinton Foundation  agreed 
price of CD4 cell count  (Rs. 
243 per test) 
1988 2583  922 




6.  Conclusion 
India stands at a critical junction of HIV pandemic. If the rate of HIV infection were to 
rise by just a few percentage points, millions more Indians will be affected by the virus.  
Ever since HIV/AIDS was acknowledged as a problem, the strategies to address the issue 
have focused on it as a disease.  Little has been done to address the root causes of 
vulnerability to infection.  The strategies in this area have focused on prevention, 
treatment and research.  This paper discussed the treatment aspect.  With currently 
available antiretroviral agents, eradication of HIV infection is not likely.  The aim of 
treatment is thus to prolong and improve the quality of life by maintaining maximal 
suppression of virus replication for as long as possible (WHO 2002).  Brazil has shown 
how to achieve success with antiretroviral therapy programme.  In Brazil, for example 
introduction of antiretroviral therapy has increased the survival time from less than 6 
months to close to 5 years.  In a study in India by YRG care, the median duration of 
survival for subjects who initiated antiretroviral therapy when their CD4 lymphocyte 
counts were less than 200 cells/mL was 45 months; for those with comparable CD4 
lymphocyte counts who did not receive antiretroviral therapy, the median duration of 
survival was only 33 months.  On the other hand effort to stop treatment in patients 
on HAART has met with limited success so far.  A critical question for any 
government considering initiation of ARV is how long the patient will have to 
continue on these drugs.  Studies have produced a varying result on the same and the 
general remark is that patient may have to continue to receive ARVs for the rest of life.  
India has embarked upon an ambitious programme to introduce antiretroviral therapy 
in six high prevalent states and the national capital.  However, there seems to be 
several missing links in the programme.  A programme of this scale needs better 
counselling in order to ensure that persons who are diagnosed and who don't need 
ARV's immediately should learn how to manage their immune function without the 
medicine, similarly they need to be counselled for their nutritional requirement which 
are crucial for patients infected with HIV.  Supply chain management is probably the  
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key issue in the programme.  To start them and then find that there are insufficient 
resources to continue the supply, such as what is now happening in Nigeria may be 
counterproductive.  A report compiled by Kaiser Family Foundation, the National 
Association of State and Territorial AIDS Directors and the AIDS treatment data 
network shows that United States itself is struggling to provide antiretroviral therapy 
to poor patients and in many cases are forced to limit the drugs in order to cut down 
cost.  The high costs of drugs has forced 1,263 patients in nine states to be on waiting 
lists as of April 2004, in spite of a 9 per cent increase in overall budget to provide the 
antiretroviral drugs to the poor patients.  
A research study (Gupta and Sankar 2003) conducted in Delhi, Mumbai and Chennai 
among people living with HIV/AIDS and undertaking treatment in several hospitals of 
the states  found that as many as 29 per cent of respondents ever been on ART 
reported non-adherence and 72 per cent of them sited economic factors as the reason 
for non-adherence.  This figure will only go to the higher side if taken at national level.  
Hence, we suggest a high degree of advocacy is needed in order to disseminate 
information regarding recent development in drugs and monitoring front of delivering 
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The information presented here are adopted from various sources 
 
Seroconversion 
Primary HIV infection occurs when HIV first enters the body, it encounters the 
immune system and begins to produce new virus (viral replication).  Seroconversion is 
the development of detectable antibodies in the blood as a result of infection, or in 
other terms going from negative HIV status to positive HIV status.  Antibodies are 
proteins produced in the body in response to a foreigner, like HIV.  They contribute to 
the destruction of the virus at first, but the virus eventually takes over leaving the host 
extremely susceptible to other infections and diseases.  It has been estimated that 95 – 
99 per cent of individuals infected with HIV will seroconvert within 6-12 weeks of 
exposure although in some it may take longer.  Two important factors in determining 
survival and progression to AIDS are age at seroconversion and time elapsed since 
seroconversion. The vast majority of people will develop AIDS within 20 years after 
seroconversion. 
 
T-Cell (CD4) Counts 
CD4 cell count correspondence to the number of T-helper lymphocytes per cubic 
millimeter of blood.  T-helper lymphocytes help to organise body's defences against 
disease.  Healthy adults and teenagers usually have a CD4 count of at least 800 cells per 
cubic millimeter of blood (a cubic millimeter is a very small amount, roughly one 
small drop).  HIV attacks CD4 cells, and as time goes by people with HIV often see their 
CD4 counts drop.  The lower the CD4 count, the greater is the chance of getting a 




The viral load refers to the level or concentration of HIV in the blood.  The level of the 
virus in the blood (viral load) indicates how fast the virus is multiplying and also how 
well or how poorly the virus is being controlled by the immune system.  There are 
several tests that can be used to measure the viral load.  These tests can measure any 
level from as low as 50 viruses per millilitre of blood (50 virus copies/ml) to as high as 
10 million viruses per millilitre.  The higher the viral load, the more rapidly the virus 
is multiplying and the more quickly a person will develop AIDS.  
 
A rough guide:  
·  Viral load higher than 100,000 copies/ml: rapid disease progression  
·  Viral load between 10,000 and 100,000 copies/ml: average disease progression  
·  Viral load lower than 10,000 copies/ml: slow disease progression.  
 
Candidiasis   
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Candidiasis is a fungal infection of the mucous membranes.  This fungus appears not 
only on mucous membranes but on the skin so there is really no way to avoid 
exposure. Candidiasis usually occurs in the mouth and throat (oral candidiasis), the 
vagina (vaginal candidiasis) and the esophagus (esophageal candidiasis). 
 
Cryptosporidiosis  
Cryptosporidiosis is caused by the protozoan parasite Crypto sporidium parvum.  
When ingested it can be responsible for an extremely debilitating illness.  The 
protozoan parasite infects cells lining in the digestive track - the small intestine, the 
airways and lung, bile duct and the colon and other gastrointestinal tract areas.  This 
opportunistic protozoan is very contagious and causes diarrhoea of varying severity in 
immuno-compromised patients.  Cryptosporidiosis is usually not an early 
opportunistic infection but normally appears in advanced stages of HIV disease. 
 
Cryptococcoses  
Cryptococcoses is the most common cause of meningitis in patients with advanced HIV 
disease and is caused by the yeast Cryptococcoses neoformanf--a harmless fungus that 
lives in soil, especially in soil fertilised by bird droppings.  This fungus is found the 
world over and when inhaled by a normal host it is contained in the lungs, but when 
inhaled by an HIV-infected person it can cause infection in the pulmonary system, the 
retina, the central nervous system, the skin, bones, lymph nodes and other 
disseminated areas. 
 
Cytomegalovirus Disease  
Cytomegalovirus (CMV) is latent in most persons with HIV - in nearly 70 per cent of 
heterosexuals and 95 per cent of gay men.  The virus typically reactivates in persons 
whose CD4 cell counts fall below 100 or, more frequently, below 50.  It can affect 
virtually any organ however, and less frequently, though increasing in incidence, can 
cause neurological disease including encephalitis and very rarely pulmonary disease 
suggesting CMV dissemination. 
 
Histoplasmosis  
Histoplasmosis is a fungal infection that affects the lungs and respiratory system.  A 
person can acquire histoplasmosis if they inhale air which contains the spores of the 
fungus Histoplasma capsulatum.  In episodes of histoplasmosis where the infected 
person has a healthy immune system, there are often no symptoms.  This is referred to 
as "acute self-limited histoplasmosis".  If the person does develop symptoms, they are 
most often flu-like in nature, such as fever, cough, fatigue and chest pain.  Symptoms 
usually appear ten days after exposure, and subside without treatment after a few 
weeks.  When symptoms disappear, it is unusual for there to be long-term ill effects. 
 
HIV-Related Malignancies: Kaposi's Sarcoma  
Kaposi's sarcoma (KS) is a lesion-producing cancer of the lining of blood vessels that 
can be disfiguring and has a clinical course than can range from incidental or minimal  
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disease to a rapid, widespread tumour growth, depending on the individual.  KS 
appears most frequently in those who acquire HIV sexually.  
 
Mycobacterium Avium Complex  
Mycobacterium avium complex or MAC disease is now regarded as one of the most 
common opportunistic infections in persons with AIDS and the most common 
bacterial infection.  It is: 
·  usually one of the last opportunistic infections to be seen in persons with AIDS and 
is usually a sign of advanced HIV progression and significant immune suppression, 
most often appearing in those with a CD4 lymphocyte account below 50 cells per 
mm.  
·  is most often preceded by a prior HIV-related opportunistic infection  
·  does not occur in any specific HIV-infected group more than another -- occurring 
in all risk groups, races and ages who have advanced HIV disease.  
 
It is believed that patients whose immune systems progressively worsen and reach CD4 
lymphocyte counts as low as 10 cells per mm are at high risk for ultimately developing 
the disease. 
 
Pneumocystis Carinii Pneumonia  
Pneumocystis carinii is a microorganism.  It does not respond to antifungal therapy, but 
shows pliancy to antiprotozoal therapy.  Pneumocystis carinii pneumonia (PCP) is the 
most common opportunistic infection seen in patients with AIDS - and has been since 
the beginning of the HIV epidemic. 
 
Toxoplasmosis  
In patients with advanced HIV disease toxoplasmosis is a common infection of the 
central nervous system where it accounts for nearly 15 per cent of central nervous 
system infections and the disease in itself is an AIDS-defining diagnosis.  T. gondii or 
toxoplasma gondii is an intracellular protozoan found in many birds and mammals as 
well as in humans who either ingest this protozoan parasite through the mouth or 




Tuberculosis occurs in 4 per cent of patients who have AIDS and in fact Mycobacterium 
tuberculosis located in any site in immunocompromised persons whose CD4 cells per 
microliter of blood are less than 200 is considered an AIDS-defining disease.  TB is an 
infectious disease and can be transmitted by microscopic particles released in the air by 
the cough or sneeze of someone with active TB, though usually infection is the result 




When to start Antiretroviral Therapy 
 
Patients diagnosed with AIDS or in an 
advanced HIV disease with severe 
symptoms irrespective of CD4+ T cell 
count 
Recommend starting therapy 
Yes 
Asymptomatic patients with CD4+ T cell 
count < 200 cells/µL 
Recommend starting therapy 
Yes 
Asymptomatic patients with CD4+ T cell 
count > 200 cells/mm3 but < 350 
cells/µL 
Consideration should be given to start 
therapy 
Yes 
Asymptomatic patients with CD4+ T cell 
count > 350 cells/µL and a viral load 
<55,000 copies/mL 
Observe the patients and wait to start 
therapy 
Yes 
Asymptomatic patients with CD4+ T cell 
count > 350 cells/µL and a viral load 
>55,000 copies/mL 
Aggressive Approach: Recommended 
starting therapy 
Yes 
Conservative Approach: Defer therapy 









  WHO staging system for HIV infection and disease in adults and adolescents 
Clinical stage I (Performance scale 1: asymptomatic, normal activity) 
1.  Asymptomatic  
2.  Persistent generalised lymphadenopathy 
    
Clinical stage II (and/or performance scale 2: symptomatic, normal activity) 
3.  Weight loss, <10% of body weight  
4.  Minor mucocutaneous manifestations (seborrheic dermatitis, prurigo, fungal nail 
infections, recurrent oral ulcerations, angular cheilitis)  
5.  Herpes zoster within the last five years  
6.  Recurrent upper respiratory tract infections (i.e. bacterial sinusitis)  
 
Clinical stage III (and/or performance scale 3: bedridden <50% of the day during the last month) 
7.  Weight loss, >10% of body weight  
8.  Unexplained chronic diarrhoea, >1 month  
9.  Unexplained prolonged fever (intermittent or constant), >1 month  
10.  Oral candidiasis (thrush)  
11.  Oral hairy leukoplakia  
12.  Pulmonary tuberculosis within the past year  
13.  Severe bacterial infections (i.e. pneumonia, pyomyositis)  
Clinical stage IV (and/or performance scale 4: bedridden >50% of the day during the last month) 
14.  HIV wasting syndrome, as defined by the Centres for Disease Control and 
Prevention
a  
15.  Pneumocystis carinii pneumonia  
16.  Toxoplasmosis of the brain  
17.  Cryptosporidiosis with diarrhoea  >1 month  
18.  Cryptococcosis, extrapulmonary  
19.  Cytomegalovirus disease of an organ other than liver, spleen or lymph nodes   
20.  Herpes simplex virus infection, mucocutaneous >1 month, or visceral any duration  
21.  Progressive multifocal leukoencephalopathy  
22.  Any disseminated endemic mycosis (i.e. histoplasmosis, coccidioidomycosis)  
23.  Candidiasis of the oesophagus, trachea, bronchi or lungs  
24.  Atypical mycobacteriosis, disseminated  
25.  Non-typhoid Salmonella septicaemia  
26.  Extrapulmonary tuberculosis  
27.  Lymphoma  
28.  Kaposi’s sarcoma  




Note: both definitive and presumptive diagnoses are acceptable. 
a.  HIV wasting syndrome: weight loss of >10% of body weight, plus either unexplained chronic 
diarrhoea (>1 month) or chronic weakness and unexplained prolonged fever (>1 month). 
b.  HIV encephalopathy: clinical findings of disabling cognitive and/or motor dysfunction 
interfering with activities of daily living, progressing over weeks to months, in the absence of a  
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concurrent illness or condition other than HIV infection which could explain the findings.  
          
 